{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736%2BTremelimumab&page=2", "query": { "intervention": "MEDI4736+Tremelimumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736%2BTremelimumab&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736%2BTremelimumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T03:13:15.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03482102", "title": "Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-05-14", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03482102" }, { "nct_id": "NCT02519348", "title": "A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 433, "start_date": "2015-10-19", "completion_date": "2026-12-18", "has_results": true, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 16, "location_summary": "Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519348" }, { "nct_id": "NCT06526104", "title": "Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Cirrhosis, Liver" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-12-02", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06526104" }, { "nct_id": "NCT06824363", "title": "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Malignant Solid Tumor", "Stomach Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-05-25", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824363" }, { "nct_id": "NCT06109272", "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-01-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109272" }, { "nct_id": "NCT03150836", "title": "Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Terence Friedlander, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-10-01", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150836" }, { "nct_id": "NCT02762006", "title": "Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Kidney Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Moshe Ornstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-12-20", "completion_date": "2020-11-06", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02762006" }, { "nct_id": "NCT02639026", "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic", "Melanoma", "Non Small Cell Lung Cancer (NSCLC)", "Breast Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-01-26", "completion_date": "2023-06-27", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639026" }, { "nct_id": "NCT02319044", "title": "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "MEDI4736 + Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "96 Years", "sex": "ALL", "summary": "18 Years to 96 Years" }, "enrollment_count": 267, "start_date": "2015-04-15", "completion_date": "2020-07-06", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Yuma, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319044" }, { "nct_id": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 730, "start_date": "2018-09-27", "completion_date": "2026-10-23", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-10T03:13:15.117Z", "location_count": 34, "location_summary": "Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703297" } ] }